Yakup Ergün: Surrogate End Points for OS in Neoadjuvant RCTs for Early Breast Cancer
Yakup Ergün, Medical Oncologist at Antalya City Hospital, posted on X about recent paper by Fabio Conforti et al., titled “Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer” published on Journal of Clinical Oncology.
Authors: Fabio Conforti, Valentina Nekljudova, Isabella Sala, Roberto Ascari, Christine Solbach, Michael Untch, Carsten Denkert, Vincenzo Bagnardi, Laura Pala, Peter A. Fasching, Andreas Schneeweiss, Hans-Joachim Lück, Eleonora Pagan, Tommaso De Pas, Marion van Mackelenbergh, Jens Huober, Volkmar Müller, Theresa Link, Thomas Karn, Mattea Reinisch, Frederik Marmé, Vesna Bjelic-Radisic, Christian Schem, Andreas Hartkopf, Elmar Stickeler, Claus Hanusch, Jens-Uwe Blohmer, Tanja Fehm, Kerstin Rhiem, Johannes Holtschmidt, Richard D. Gelber, Sibylle Loibl
“Surrogate End Points for OS in Neoadjuvant RCTs for Early BC. Eleven RCTs, 12,247 patients.
pCR is a poor surrogate for OS at the trial level.
In studies with sufficient follow-up, iDFS is a strong surrogate for OS, except in the HR+ subgroup.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023